The Uromigos Episodes by Conference
ASCO
Yohann Loriot, MD, PhD, discusses the practice-changing THOR study data on the benefit of erdafitinib for advanced UC.
Meredith Regan and David McDermott finalize their debate on VEGF/TKI vs IPI/NIVO for mRCC. PFS2 and TFS are also covered.
Advertisement
ASCO GU
Reviewing the top presentations from ASCO GU 2024, including the phase III GETUG-AFU-18 study, CONTACT-02, and more.
Dr. Agarwal discusses the CONTACT-02 trial that analyzed the use of cabozantinib in combination with atezolizumab for mCRPC.
Advertisement
EAU
Dr. Galsky describes the OS signal data from CheckMate-274 on adjuvant nivolumab for muscle-invasive bladder cancer.
Dr. Matt Galsky, Brian, and Tom discuss the IMvigor011 trial data that was presented at EAU 2024.
ESMO
Silke Gillessen, MD, PhD recaps some of the kidney, bladder, and prostate cancer data from this year's ESMO meeting.
Dr. Kevin Kelly discusses the AMG509 phase 1 study of xaluritamig, a bispecific T cell engager, for prostate cancer.
IKCS
Tian Zhang joins the podcast to give an overview of some of the panels presented at this year's IKCS meeting.
The Uromigos: Live & Unplugged
Dr. Powles chaired a livestreamed RCC session that included lively discussion from Drs. Atkins, McDermott, and Rini.
The panel highlights a serious of relevant studies in renal cell carcinoma, including CONTACT-03 and TiNivo-2.
